Author Affiliation: Interdisciplinary Stem Cell Institute, University of Miami, Miami, Florida.
The results of the LateTIME study,1 reported by Traverse and colleagues in this issue of JAMA, appear 1 decade after the publication of the landmark study by Orlic et al.2 The authors conducted a rigorous clinical trial to test the hypothesis that intracoronary infusion of autologous bone marrow mononuclear cells (BMCs) in patients with myocardial infarction (MI) would improve left ventricular function. The rationale for using whole bone marrow in this setting derives from numerous sets of experimental studies showing that bone marrow contains cellular constituents that have cardiac reparative ability.2,3 The authors found that among 87 patients with MI and left ventricular dysfunction following reperfusion with percutaneous coronary intervention, compared with placebo intracoronary infusion, intracoronary infusion of BMCs 2 to 3 weeks after percutaneous coronary intervention did not improve global or regional ventricular function at 6 months.
Hare JM. Bone Marrow Therapy for Myocardial Infarction. JAMA. 2011;306(19):2156-2157. doi:10.1001/jama.2011.1686